RSPRY1 Inhibitors
RSPRY1 inhibitors encompasses a group of small molecules that have been designed and developed to target a specific molecular pathway within cells. RSPRY1, or Ras and Rab interactor 1, is a protein that plays a crucial role in regulating the Ras signaling pathway. This pathway is integral to various cellular processes, including cell growth, differentiation, and survival. Specifically, RSPRY1 acts as a negative regulator of this pathway by binding to and promoting the degradation of key signaling proteins involved in cell proliferation and survival. RSPRY1 inhibitors, as the name suggests, are compounds designed to interfere with the function of RSPRY1, ultimately leading to the activation of the Ras pathway and impacting downstream cellular processes.
The mechanism of action of RSPRY1 inhibitors typically involves blocking the degradation of Ras pathway signaling proteins. When RSPRY1 is inhibited, it cannot promote the degradation of these proteins, allowing them to accumulate and activate the Ras pathway. This activation, in turn, leads to increased signaling through the mitogen-activated protein kinase (MAPK) cascade and the extracellular signal-regulated kinase (ERK) pathway. These signaling events culminate in a variety of cellular responses, such as increased cell proliferation and survival. Therefore, RSPRY1 inhibitors act as modulators of this critical signaling pathway, and their development and study have provided valuable insights into the intricate mechanisms of cellular regulation. It is important to note that while RSPRY1 inhibitors hold for various applications, their primary role in research lies in elucidating the complexities of cell signaling pathways and their implications for cell biology and disease progression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Encorafenib is a selective BRAF kinase inhibitor that targets RSPRY1 indirectly by inhibiting the MAPK/ERK pathway. It blocking the phosphorylation of MEK and ERK, disrupting downstream signaling and inhibiting tumor cell proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that indirectly affects RSPRY1 by inhibiting the RAF/MEK/ERK pathway, leading to decreased cell proliferation and angiogenesis in cancer cells. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib specifically targets mutated BRAF, leading to downstream inhibition of MEK and ERK. By suppressing MAPK signaling, it reduces cell proliferation and induces apoptosis in melanoma cells. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a selective MEK inhibitor that indirectly affects RSPRY1 by blocking the MEK/ERK pathway. It hinders cell growth and division in cancer cells with activated MAPK signaling, such as melanoma. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Dabrafenib is a selective BRAF kinase inhibitor that disrupts the MAPK/ERK pathway. By inhibiting the phosphorylation of MEK and ERK, it impairs cell growth and division in BRAF-mutated melanoma cells. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
Binimetinib is a MEK inhibitor that indirectly affects RSPRY1 by blocking the MEK/ERK pathway. It inhibits cell proliferation and tumor growth in various cancers with MAPK pathway activation. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib is a selective MEK inhibitor that indirectly affects RSPRY1 by inhibiting the MEK/ERK pathway. It suppresses tumor cell proliferation and has been approved for the therapy of melanoma. | ||||||
TAK 632 | 1228591-30-7 | sc-473801 | 5 mg | $228.00 | ||
TAK-632 is a potent and selective pan-RAF inhibitor that indirectly affects RSPRY1 by disrupting the MAPK/ERK pathway. It inhibits cell growth and division in cancer cells with RAS and RAF pathway aberrations. | ||||||
LY3009120 | 1454682-72-4 | sc-507538 | 5 mg | $125.00 | ||
LY3009120 is a selective pan-RAF inhibitor that targets RSPRY1 indirectly by inhibiting the RAF/MEK/ERK pathway. It inhibits cell proliferation and has potential therapeutic applications in RAF-mutant cancers. | ||||||